Sinopharm Group CoSHTDY +2.87%73 Net Debt Paydown Yield % is 7.87% as of Jul. 05, 2026. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.05 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 104 Medical Distribution companies, Sinopharm Group Co ranks better than 76.92% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Sinopharm Group Co's Net Debt Paydown Yield % was 7.87%.
Sinopharm Group Co (OTCPK:SHTDY) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Sinopharm Group Co Net Debt Paydown Yield % Related Terms
Sinopharm Group Co Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDY vs MCK, CAH, COR: Net Debt Paydown Yield % Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Net Debt Paydown Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 7.87% mean?
Sinopharm Group Co (SHTDY) has a Net Debt Paydown Yield % of 7.87% as of Jul. 05, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #24 out of 104 companies in the Medical Distribution industry, placing it in the top 23.1%.
Is Sinopharm Group Co's Net Debt Paydown Yield % too high?
Sinopharm Group Co's current Net Debt Paydown Yield % is 7.87%. The Medical Distribution industry median Net Debt Paydown Yield % is 0.03. Sinopharm Group Co's value of 7.87% is 26133.3% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #24 out of 104 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Net Debt Paydown Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #24 out of 104 companies for Net Debt Paydown Yield %. This places Sinopharm Group Co in the top 23% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Sinopharm Group Co's value of 7.87% is 26133.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Distribution company?
The median Net Debt Paydown Yield % among Medical Distribution companies is 0.03, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Net Debt Paydown Yield % of 7.87% is 26133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Net Debt Paydown Yield % is 7.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $10.45 — trading 19.9% below its estimated fair value. The current Net Debt Paydown Yield % is 7.87% and 26133.3% above the Medical Distribution industry median of 0.03. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Net Debt Paydown Yield % is 7.87% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.45 is trading 19.9% below its estimated GF Value™ of $13.05.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Net Debt Paydown Yield %: 7.87%
GF Value™: $13.05 vs. price of $10.45 (19.9% below fair value)
Industry Position: 26133.3% above the Medical Distribution median (#24 of 104)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
